Literature DB >> 17899549

Programmed cell death 1 (PD-1) and its ligand PD-L1 are required for allograft tolerance.

Liqing Wang1, Rongxiang Han, Wayne W Hancock.   

Abstract

Programmed cell death-1 (PD-1, CD279) and its widely expressed, inducible ligand, PD-L1 (CD274), together dampen T cell activation, but whether they are essential for allograft tolerance is unknown. We show, using gene-deficient mice and blocking mAbs in wild-type mice, that costimulation blockade is ineffectual in PD-1(-/-) or PD-L1(-/-) allograft recipients, or in wild-type allograft recipients treated with anti-PD-1 or anti-PD-L1 mAb. Alloreactive PD-1(-/-) CD4 and CD8 T cells had enhanced proliferation and cytokine production compared to wild-type controls, and anergy could not be induced in PD-1-deficient CD4 T cells. We conclude that without inhibitory signals from PD-1 ligation, alloantigen-induced T cell proliferation and expansion cannot be regulated by costimulation blockade, and peripheral tolerance induction cannot occur.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17899549     DOI: 10.1002/eji.200737583

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  33 in total

1.  PD-L1(hi) retinal pigment epithelium (RPE) cells elicited by inflammatory cytokines induce regulatory activity in uveitogenic T cells.

Authors:  Yan Ke; Deming Sun; Guomin Jiang; Henry J Kaplan; Hui Shao
Journal:  J Leukoc Biol       Date:  2010-08-25       Impact factor: 4.962

2.  PD-1 signalling in CD4(+) T cells restrains their clonal expansion to an immunogenic stimulus, but is not critically required for peptide-induced tolerance.

Authors:  Joanne E Konkel; Friederike Frommer; Melanie D Leech; Hideo Yagita; Ari Waisman; Stephen M Anderton
Journal:  Immunology       Date:  2010-01-27       Impact factor: 7.397

Review 3.  T-cell costimulatory blockade in organ transplantation.

Authors:  Jonathan S Maltzman; Laurence A Turka
Journal:  Cold Spring Harb Perspect Med       Date:  2013-12-01       Impact factor: 6.915

4.  Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes.

Authors:  Asaka Kondo; Taishi Yamashita; Hideto Tamura; Wanhong Zhao; Takashi Tsuji; Masumi Shimizu; Eiji Shinya; Hidemi Takahashi; Koji Tamada; Lieping Chen; Kazuo Dan; Kiyoyuki Ogata
Journal:  Blood       Date:  2010-05-14       Impact factor: 22.113

5.  FOXP3+ regulatory T cell development and function require histone/protein deacetylase 3.

Authors:  Liqing Wang; Yujie Liu; Rongxiang Han; Ulf H Beier; Tricia R Bhatti; Tatiana Akimova; Mark I Greene; Scott W Hiebert; Wayne W Hancock
Journal:  J Clin Invest       Date:  2015-02-02       Impact factor: 14.808

6.  PD-1 expression on CD8+ T cells regulates their differentiation within lung allografts and is critical for tolerance induction.

Authors:  T Takahashi; H M Hsiao; S Tanaka; W Li; R Higashikubo; D Scozzi; A Bharat; J H Ritter; A S Krupnick; A E Gelman; D Kreisel
Journal:  Am J Transplant       Date:  2017-08-23       Impact factor: 8.086

Review 7.  T-cell exhaustion in allograft rejection and tolerance.

Authors:  Edward B Thorp; Christian Stehlik; M Javeed Ansari
Journal:  Curr Opin Organ Transplant       Date:  2015-02       Impact factor: 2.640

8.  The link between the PDL1 costimulatory pathway and Th17 in fetomaternal tolerance.

Authors:  Francesca D'Addio; Leonardo V Riella; Bechara G Mfarrej; Lola Chabtini; La Tonya Adams; Melissa Yeung; Hideo Yagita; Miyuki Azuma; Mohamed H Sayegh; Indira Guleria
Journal:  J Immunol       Date:  2011-09-26       Impact factor: 5.422

Review 9.  T Cell Cosignaling Molecules in Transplantation.

Authors:  Mandy L Ford
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

Review 10.  Role of the PD-1 pathway in the immune response.

Authors:  L V Riella; A M Paterson; A H Sharpe; A Chandraker
Journal:  Am J Transplant       Date:  2012-08-17       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.